Compare GeneDx Holdings Corp (WGS) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Williams Companies Inc — how do they compare? GeneDx Holdings Corp trades at $67.77 (market cap $2.02B), while Williams Companies Inc trades at $72.74 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 43.8× GeneDx Holdings Corp's market cap, and Williams Companies Inc pays a 2.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Williams Companies Inc for 58 Days on average.
| WGS | WMB | |
|---|---|---|
Market Cap | $2.02B | $88.48B |
Volume | 734,640 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $167.51 | $79.40 |
52-Week Low | $34.51 | $56.51 |
Typical Hold Time | 19 Days | 58 Days |
Enterprise Value | $2.05B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Williams Companies (WMB) trades at $72.68, up 1.71% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while Q2 narrowly missed. Technical indicators signal bullish momentum with support at $71-$72 and resistance at $73-$74. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.27 price target upside. Key risks include energy market volatility and high debt levels. The AI-driven data center growth provides tailwinds for natural gas demand, supporting long-term revenue stability. Investors should weigh the attractive dividend yield against exposure to commodity price fluctuations and capital expenditure requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
